There's a time when you can take it differently, but I feel like it's just a part of my story and a part of my health journey," says Williams
Upcoming 2026 readouts TRIUMPH-1: the pivotal general obesity study TRIUMPH-1 is the trial that will anchor the weight-management NDA
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon (GCG) receptor This triple G mechanism targets multiple pathways for appetite control, insulin sensitivity, glucose regulation, and energy/fat metabolismpotentially offering greater effects than dual (GLP-1/GIP) or single agonists
Are there any ways to manage menstrual irregularities caused by semaglutide
12 The pharmaceutical industry lobbied for Patent Term Extensions under the Hatch-Waxman Act 1984 to ensure they would be guaranteed up to 14 years of market protection from the date of a products approval
Period tracking apps (Clue, Flo, Apple Health) capture cycle length, flow heaviness, and PMS symptoms
